Koutif Therapeutics aims to develop therapeutic compounds that inhibit the inflammatory cascade in a unique manner. Our medicinal chemistry strategy is based upon discoveries by Rama Mallampalli, MD and Beibei Chen, PhD on inhibitors of the ubiquitin degradation pathway that Koutif has licensed from the University of Pittsburgh.
Inflammation plays a critical role in the progression of many diseases. One way of modulating this process is through the degradation of key proteins (TRAFs and the NLRP3 inflammasome) involved in the activation cascade. Fbxo3, an E3 ligase, is a negative regulator of this control process resulting in a continuation of the inflammation cascade. Drs. Mallampalli and Chen identified a specific inhibitor of Fbxo3 that acts to allow the degradation of several potent, pro-inflammatory proteins, including multiple proteins involved in adaptive and innate immune signaling pathways. This novel mechanism has the potential to treat numerous inflammatory conditions.
“Fbxo3 has never been targeted before and represents a truly breakthrough method for treating a variety of conditions.”
Intellectual Property
Our technology is based on intellectual property exclusively licensed from the University of Pittsburgh and the United States Department of Veterans Affairs.